Table 5.

Sensitivity analysis: percent of confirmed (CHB) patients noted to be UTD* for CHB management in three care groups: 1) CIH pilot, both as one group and divided into two groups for exploratory analysis based on whether the patients had been seen by a liver specialist (CIH + GI); 2) GI; and 3) HP PC at baseline (September 1, 2019) and pilot registry end date (February 28, 2020); n = 2,463

	CIH
	CIH, n = 174	CIH + GI/ CIH no GI, n = 72/102	GI, n = 616	PC, n = 1,673
Baseline	57%	81%/40%	71%	16%
Pilot registry end date	67%	79%/59%	60%	15%

CHB = chronic hepatitis B; CIH = HealthPartners Center for International Health; GI = HealthPartners Gastroenterology; HBV = hepatitis B virus; PC = HealthPartners Primary Care.

^*Up-to-date (UTD) = alanine transaminase and hepatitis B virus DNA laboratory testing as well as hepatocellular carcinoma screening by ultrasound, contrast-enhanced computed tomography, or magnetic resonance study performed within the 12 months of selected time points.